AvevoRx delivers innovative solutions for 340B Covered Entities seeking to expand and optimize their home infusion programs. Our approach is designed to maximize program performance, enhance patient access, and unlock incremental savings through a more comprehensive claims strategy.

Unlike many specialty pharmacies, AvevoRx captures and reports both pharmacy and major medical claims data, ensuring Covered Entities benefit from a broader and more complete view of eligible utilization. By incorporating medical claims into the 340B program, we help expand eligibility and significantly increase overall savings potential.

Our program consistently demonstrates strong performance, with an average 43% eligibility capture rate—surpassing national benchmarks. This success is driven by our ability to identify and report opportunities that are often overlooked when relying on pharmacy claims alone.

AvevoRx also provides strategic guidance to help Covered Entities maximize value across their infusion programs. This includes:

• Advising on product selection to optimize 340B savings
• Conducting pharmacist-led medication reviews to identify safe, effective clinical alternatives
• Expanding access to infusion therapies for patients both within and beyond your core service area

With national coverage, we help capture eligible claims wherever patients receive care—improving continuity, supporting overflow needs, and driving higher internal capture rates.

Our expertise spans high-impact infusion therapies, including Immunoglobulins, TNF blockers, and Alpha-1, ensuring your program is aligned with the therapies that matter most.

By combining deep clinical insight with comprehensive claims reporting, AvevoRx empowers Covered Entities to fully realize the value of their 340B infusion programs.